Use of two novel antibodies that detect tumor-specific antigens for the detection of colorectal cancer.

e21082 Background: The early diagnosis of colorectal cancers remains an area of high unmet medical need, as underscored by the U.S. estimated combined, annual death rate of >89,000. These cancers are currently diagnosed with non-laboratory procedures that are often invasive and expensive. As an alternative diagnostic approach, we developed immunohistochemistry (IHC) tests based upon two unique promising novel tumor-specific monoclonal antibodies generated against a clinically tested human colon cancer vaccine. NPC-1C and 16C3 are two novel monoclonal antibodies that bind to antigen-specific targets expressed on colorectal cancer tissues and cells with little cross-reactivity to normal tissues. The NPC-1C antibody binds to a variant of MUC5AC whereas the 16C3 antibody binds to variants of CEACAM-5 and CEACAM-6. The aim of this study was to evaluate the use of the NPC-1C and 16C3 antibodies as potential new tools for colorectal cancer diagnosis and for future application as novel biological treatments for c...